News & Events

OpSens Announces 510(K) Submission to U.S. FDA for New Guidewire for the TAVR Procedure Quebec City, Quebec, December 13, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today announced that it has filed a 510(k) submission with the U.S….

Read more

OPSENS TO PRESENT AT THE LYTHAM PARTNERS WINTER 2021 INVESTOR CONFERENCE Presentation at 11 AM (ET), Monday December 13, 2021   Quebec, Quebec, December 7, 2021 – OpSens inc. («OpSens» or the «Company») (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, announced today that it will be…

Read more

OpSens Announces Fourth Quarter And Fiscal Year 2021 Financial Results Conference call on the results today at 11 a.m. ET Quebec City, Quebec, November 23, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today reported its results for the…

Read more

OpSens Successfully Completes 20-Patient In-Human Clinical Study for TAVR Procedure TAVR market outlook for procedural growth remains highly attractive globally Quebec City, Quebec, November 23, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary technology, is pleased to announce the successful treatment…

Read more

OpSens to Host Fourth Quarter Fiscal Year 2021 Financial Results Conference Call and Year-End Update on Tuesday, November 23, 2021 Conference call to be conducted at 11:00 am ET Quebec City, Quebec, November 17, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering diagnostic and treatment solutions based…

Read more

OpSens Will Participate at Stifel 2021 Virtual Healthcare Conference and Canaccord Genuity  MedTech & Diagnostics Forum    Quebec City, Quebec, November 10, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF),  a medical device cardiology-focused company commercializing a  second-generation fiber optic pressure guidewire to diagnose and treat coronary artery disease, announced today that Louis…

Read more

OpSens’ SavvyWire™ Featured at the Transcatheter Cardiovascular Therapeutics 2021 Annual Meeting in Orlando  Quebec City, Quebec, November 8, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF),  a medical device company currently commercializing its proprietary sensing technology in the interventional cardiology market, announced that its SavvyWire, developed specifically for transcatheter aortic valve replacement (“TAVR”),…

Read more

OpSens Successfully Treats First Patients in Human Clinical Study for TAVR Procedure Quebec, Quebec, October 13, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a cardiology medical device company providing innovative product solutions based on its patented optical technology, is pleased to announce the commencement of the human clinical study utilizing the SavvyWire,…

Read more

OPSENS TO PRESENT AT THE LYTHAM PARTNERS FALL 2021 INVESTOR CONFERENCE Presentation at 9:30 AM, Tuesday October 5, 2021  Quebec, Quebec, September 29, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a cardiology medical device company providing innovative product solutions based on its patented optical technology, announced today that it will present at…

Read more